Foster Electric <6794>: 1486 yen (-333 yen)

Significant decline. The company held a briefing on the first half financial results the previous day, as well as announcing its medium-term business plan. In the mid-term plan, they set a target for the final year ending March 2028 with revenue of 150 billion yen (forecast for March 2025: 135 billion yen), operating profit of 9 billion yen (compared to 6.5 billion yen), and a target ROE of 8.0%. They also announced measures to enhance shareholder returns, such as raising the dividend payout ratio to 40% and lowering the lower limit of DOE to 2%. However, with limited surprises in the target numbers, it appears that they are expecting a decline in operating profit for the year ending March 2026, which is viewed negatively.

Sumitomo Pharma <4506>: 614 yen (+21 yen)

A significant rebound is observed. It is reported that a "airlift operation" using nerve cells made from iPS cells is being launched to treat Parkinson's disease in the usa, leading to material considerations. Cells will be provided for clinical trials at the University of California, San Diego, and treatment is expected to be implemented within this fiscal year. To ensure the delivery of stable quality cells, collaboration with Mitsubishi Warehouse, Inabata & Co., and All Nippon Airways appears to be underway. It is said that this could lead to the pioneering export of japan's cell manufacturing technology.

Misosakura Works <6584>: 797 yen (+41 yen)

Sharp increase. They have announced the development of a new model of water-cooled cooling equipment for data centers, leading to expectations for future developments. This fin pipe type cooling device announced this time has the same functionality as the pipe type cooling device announced in February, but by processing the pipe surface with fins, the heat exchange rate is increased. As a result, the new model achieves the same heat exchange performance as the previous model with a quarter of the equipment depth and half the weight, enabling a significant reduction in size and weight.

Kosaido HD <7868>: 505 yen (+51 yen)

Significant rebound. They announced the implementation of a share buyback the previous day. They plan to acquire up to 3 million shares, equivalent to 2.08% of the issued shares, with a limit of 1.65 billion yen as the acquisition amount. The acquisition period is from November 21st to January 31st of the year 25. The purpose of the acquisition is to enhance shareholder returns, improve capital efficiency, and pursue a flexible capital policy in response to changes in the business environment. This share buyback by the company is believed to be the first since it was implemented in off-hours trading in June 23. Expectations for improved supply and demand dynamics are leading the way.

Advantest <6857>: ¥9280 (-¥261)

Significant decline. On the previous day, USA Nvidia announced its financial results. For the August-October period, the revenue increased by 94% year-on-year, and the EPS on a continuing operations basis also doubled, both exceeding market expectations. In addition, the company's planned range for the November-January period anticipates revenue increasing by 70% to $37.5 billion, surpassing the market's expected $37.1 billion, with a forecasted gross profit margin of 73.5%, down from the previous year's 76.7% for the same period. Overall, it was a strong earnings report as expected, but in extended hours trading, there is a decline and selling pressure is spreading to domestic semiconductor-related companies as well.

Kaiohm <4583>: ¥150 Ka -

Limit up with buying interest. After the close of trading on the 20th, it was announced that the company had signed an exclusive licensing agreement with Asahi Kasei Pharma for the company's therapeutic antibody 'Humanized anti-CX3CR1 antibody', considered positive news. PFKR granted Asahi Kasei Pharma exclusive worldwide development, manufacturing, and sales rights with sublicensing rights. In addition to receiving a one-time contract fee of ¥0.2 billion, the company will receive milestone payments of up to approximately ¥24.8 billion based on future developments and sales progress. Furthermore, upon product launch, it will receive royalties based on product revenue.

Axel M <3624>: ¥132 (+¥14)

Sharp rise. Ascella Biosystems Inc.'s parent company has secured a $0.6 million research grant from the RADx program of the US National Institutes of Health for the development of infectious disease diagnostic technology. This funding will be a crucial support for the development of the innovative diagnostic technology 'AscellaOne' that can rapidly detect multiple respiratory pathogens including COVID-19, allowing for highly accurate and rapid diagnosis, early detection of infections, and quick treatment, especially designed for testing facilities and at-home use during pandemics.

Simbio Pharma <4582>: ¥241 (+¥3)

Rebound. They announced that they will present research findings on the potential combination therapy of the injection drug Brinsidofvir with an immune checkpoint inhibitor for non-Hodgkin lymphoma resulting from collaborative research with the National Cancer Centre Singapore at the 66th American Society of Hematology Annual Meeting to be held in San Diego, California, from December 7th to 10th, receiving positive feedback. Non-Hodgkin lymphoma is a disease in which lymphocytes become cancerous, collectively known as B-cell lymphoma and T-cell/NK-cell lymphoma, accounting for over 90% of malignant lymphomas.